Peptides (Weight Loss)

Ozempic (semaglutide), is primarily prescribed for managing type 2 diabetes and, in some cases, for weight loss under medical supervision. Ideal candidates for Ozempic typically meet specific medical and lifestyle criteria, ensuring the treatment’s efficacy and safety.

The primary candidates are adults diagnosed with type 2 diabetes who struggle to control blood sugar levels through diet, exercise, or oral medications. Ozempic enhances insulin secretion and reduces glucagon levels, helping stabilize blood glucose. Candidates often have an A1C level above 7%, indicating poor glycemic control, and may face complications like cardiovascular risks.

Ozempic is also approved for weight management in non-diabetic individuals with a body mass index (BMI) of 30 or higher (obesity) or 27 or higher (overweight) with weight-related issues, such as hypertension or dyslipidemia. Candidates should demonstrate difficulty losing weight through lifestyle changes alone, as Ozempic’s appetite-suppressing effects can lead to 10-15% body weight reduction over 6-12 months, per clinical trials.

Ideal candidates are willing to adopt a calorie-controlled diet and regular physical activity. Ozempic enhances weight loss and glycemic control but works best alongside sustainable lifestyle modifications. Candidates should be motivated to adhere to long-term treatment plans, as discontinuation often leads to weight regain or glucose spikes.